CurrentCareSourcePolicy N/A

Hemophilia Factor VIII and von Willebrand Factor Products Utilization Management Medical Policy

Prior authorization policy governing coverage, dosing, and authorization criteria for recombinant, extended half-life, standard half-life, and plasma‑derived Factor VIII products (some containing von Willebrand factor) for treatment of Hemophilia A and von Willebrand disease for CareSource members.

Policy Summary

PayerCareSource

PolicyHemophilia Factor VIII and von Willebrand Factor Products Utilization Management Medical Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateFeb 19, 2025

Key ActionObtain prior authorization and document that the agent is prescribed by or in consultation with a hemophilia specialist.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

~20 productsProducts listed

1 yearAuth duration

200 IU/kgMax IRT dosing

60–100 IU/kgRoutine prophylaxis

Recommended Authorization and Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage for listed recombinant and standard half‑life Factor VIII products (Adynovate, Eloctate, Esperoct, Jivi, Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha)

Covered when ALL of the following are met

Prescriber: Agent is prescribed by or in consultation with a hemophilia specialist

Supportive documentation required; approve for 1 year when criteria met

Indication: Diagnosis of Hemophilia A corresponding to the FDA‑approved indication

Approve for 1 year when criteria met

Dosing options

EHL products dosing: Routine prophylaxis: approve up to 100 IU/kg IV no more frequently than twice weekly; On‑demand treatment: approve up to 65 IU/kg IV no more frequently than every 8 hours for up to 10 doses per episode; Perioperative management: approve up to 65 IU/kg IV no more frequently than every 6 hours for up to 10 doses per procedure
Applies to Adynovate, Eloctate, Esperoct, Jivi
SHL recombinant dosing: Routine prophylaxis: approve up to 60 IU/kg IV no more frequently than every other day (three or four times weekly); On‑demand treatment: approve up to 50 IU/kg IV no more frequently than every 6 hours for up to 10 doses per episode; Perioperative management: approve up to 60 IU/kg IV no more frequently than every 6 hours for up to 10 doses per procedure
Applies to Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha
Immune tolerance therapy: Immune tolerance induction: approve up to 200 IU/kg IV no more frequently than once daily where indicated
Product‑specific; documented indication required

Coverage for plasma‑derived Hemofil M and Koate

Covered when ALL of the following are met

Prescriber: Agent is prescribed by or in consultation with a hemophilia specialist

Approve for 1 year

Indication: Diagnosis of Hemophilia A consistent with the FDA‑approved indication

Dosing per policy

Dosing options

Routine prophylaxis: Approve up to 50 IU/kg IV no more frequently than every other day (three or four times weekly)
Applies to Hemofil M and Koate
On‑demand treatment: Approve up to 50 IU/kg IV no more frequently than every 6 hours for up to 10 doses per episode
Immune tolerance therapy: Approve up to 200 IU/kg IV no more frequently than once daily

Coverage for Alphanate, Humate‑P, and Wilate (vWF‑containing products)

Covered when ONE of the following indication groups is met

Hemophilia A: Prescribed for Hemophilia A and prescribed by or in consultation with a hemophilia specialist; dosing per policy (routine prophylaxis, on‑demand, perioperative, or immune tolerance as detailed); approve for 1 year

Includes product dosing per FDA‑approved regimens

Von Willebrand disease: Prescribed for von Willebrand disease and prescribed by or in consultation with a hemophilia specialist; dosing per policy (for example, up to 80 IU VWF:RCo/kg IV no more frequently than every 8 hours for up to 10 days for episodes or procedures); approve for 1 year

Wilate is FDA‑approved for routine prophylaxis in children ≥6 years and adults with VWD

Dosing Guidance and Coding-related Thresholds

Dosing thresholds — Product-specific dosing ranges

Routine prophylaxis (general)Common routine prophylaxis dosing commonly 50–100 IU/kg; specific limits vary by product class (see product-specific rows).

EHL products (Adynovate, Eloctate, Esperoct, Jivi)Routine prophylaxis: up to 100 IU/kg IV no more frequently than twice weekly; On‑demand: up to 65 IU/kg IV every 8 hours for up to 10 doses; Perioperative: up to 65 IU/kg IV every 6 hours for up to 10 doses.

SHL recombinant products (Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha)Routine prophylaxis: up to 60 IU/kg IV every other day (three or four times weekly); On‑demand: up to 50 IU/kg IV every 6 hours for up to 10 doses; Perioperative: up to 60 IU/kg IV every 6 hours for up to 10 doses.

Plasma‑derived products (Hemofil M, Koate)Routine prophylaxis: approve up to 50 IU/kg IV every other day (three or four times weekly); On‑demand: up to 50 IU/kg IV every 6 hours for up to 10 doses; Immune tolerance: up to 200 IU/kg IV daily where indicated.

Immune tolerance inductionApprove up to 200 IU/kg IV no more frequently than once daily for immune tolerance therapy when indicated.

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior authorization required

Prior Authorization is recommended for medical benefit coverage of the listed Factor VIII and vWF-containing products; approval is recommended for members who meet the Criteria and Dosing in this policy and approvals are provided for the duration noted in the policy.

Step Therapy

Step therapy (none specified)

No explicit step-therapy sequence is specified between products; the policy recommends that agents be prescribed by or in consultation with a hemophilia specialist and that approvals are provided for the durations noted (typically 1 year).

Documentation Required

Prescriber and dose documentation

The agent must be prescribed by or in consultation with a hemophilia specialist; requests for doses outside the dosing established in this policy will be considered on a case‑by‑case basis by a clinician.

Supportive documentation that the prescriber is a hemophilia specialist or that consultation occurred is required.
Document requested dosing and indicate if it differs from the product-specific dosing regimens in the policy.

Denial Risk

Non‑listed indications — denial risk

Coverage requests that do not meet the Recommended Authorization Criteria or that are for circumstances not listed in the Recommended Authorization Criteria are not recommended for approval.

Clinical Background

Hemophilia A is an X‑linked deficiency of Factor VIII; disease severity is classified by plasma Factor VIII activity with severe defined as <1% activity, moderate as 1–5%, and mild as >5–40%. Approximately half of patients have severe disease and may require routine prophylactic Factor VIII therapy.

Key Definitions and Disease Severity

Severity categories for Hemophilia A

SevereFactor VIII activity < 1% of normal.

ModerateFactor VIII activity 1% to 5% of normal.

MildFactor VIII activity > 5% to 40% of normal.

Von Willebrand disease types

Type 1Partial deficiency of von Willebrand factor.

Type 2Qualitative variants divided into 2A, 2B, 2M, and 2N based on phenotype.

Type 3Complete deficiency of von Willebrand factor (rare); often associated with very low Factor VIII levels.